A detailed history of Core Cap Advisors, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 68 shares of MDGL stock, worth $21,980. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68
Holding current value
$21,980
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$212.22 - $292.96 $14,430 - $19,921
68 New
68 $14,000
Q1 2024

Aug 08, 2024

BUY
$171.37 - $283.23 $11,653 - $19,259
68 New
68 $18,000
Q4 2022

Feb 10, 2023

BUY
$58.39 - $296.54 $3,970 - $20,164
68 New
68 $19,000
Q2 2022

Aug 11, 2022

BUY
$58.04 - $100.2 $3,946 - $6,813
68 New
68 $5,000
Q1 2022

Apr 29, 2022

SELL
$55.89 - $101.89 $3,800 - $6,928
-68 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$72.34 - $95.09 $4,919 - $6,466
68 New
68 $6,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.53B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Core Cap Advisors, LLC Portfolio

Follow Core Cap Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Cap Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Core Cap Advisors, LLC with notifications on news.